Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a Multi-Center, Dose-Escalation Study to Evaluate the Safety & Efficacy of Eyecyte-RPE™ When Administered as a Single-dose Subretinal Injection in Subjects With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration

NCT06394232 is registered in ClinicalTrials.gov with Eyestem Research Pvt. Ltd. as lead sponsor.

NCT NCT06394232
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06394232 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a Multi-Center, Dose-Escalation Study to Evaluate the Safety & Efficacy of Eyecyte-RPE™ When Administered as a Single-dose Subretinal Injection in Subjects With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
Lead sponsor
Eyestem Research Pvt. Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 4, 2024
Completion date
December 31, 2030
Enrollment
54 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

age-related macular degeneration, eye diseases, geographic atrophy, macular degeneration, retinal disease